Hotgen Biotech forecasts CNY 38.5m in related transactions for 2025

Beijing Hotgen Biotech (SSE:688068) has announced its forecast for routine related-party transactions in 2025, estimating a total value of ¥38.5 million. This marks an increase of ¥10.5 million compared to the previous year's projection. The transactions primarily involve sales to and purchases from related parties, including Beijing Senpro Biotechnology, Beijing Shunjing Biomedical Technology, and Beijing Yaojing Gene Technology. The company states that these transactions are based on fair market prices and are necessary for its normal business operations, and that approval procedures have been followed to protect company and shareholder interests. The board has approved the forecast, with related-party directors abstaining from the vote.